The introduction of chapter 86 in the USP is significant as it formally endorses the recombinant Factor C (rFC) assay, moving away from the traditional Limulus amebocyte lysate (LAL) test derived from horseshoe crab blood.
This shift illustrates a broader trend in the biomedical industry towards synthetic alternatives that reduce dependence on natural bioproducts, reflecting evolving ethical considerations.
[
Collection
]
[
|
...
]